Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation

Journal of the American College of Cardiology

Volumn 69, Issue 20, 2017, Pages 2475-2484

  Marzec, Lucas N ^a,b   Wang, Jingyan ^c   Shah, Nilay D ^d   Chan, Paul S ^c   Ting, Henry H ^e   Gosch, Kensey L ^c   Hsu, Jonathan C ^f   Maddox, Thomas M ^b  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Eastern Colorado Veterans Health Care System   (United States)

^c SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^d MAYO CLINIC   (United States)

^e The University Hospital of Columbia and Cornell University ^*  (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atrial fibrillation; direct oral anticoagulants; oral anticoagulation

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN;

AGED; ARTICLE; ATRIAL FIBRILLATION; CHA2DS2 VASC SCORE; CHADS2 SCORE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; TREND STUDY; CLASSIFICATION; CLINICAL PRACTICE; COMPLICATION; HEALTH CARE DELIVERY; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; NEEDS ASSESSMENT; ORAL DRUG ADMINISTRATION; ORGANIZATION AND MANAGEMENT; REGISTER; STANDARDS; STATISTICS AND NUMERICAL DATA; STROKE; TOTAL QUALITY MANAGEMENT; TRENDS; UNITED STATES;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ANTITHROMBINS; ATRIAL FIBRILLATION; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MALE; MEDICATION THERAPY MANAGEMENT; MIDDLE AGED; NEEDS ASSESSMENT; PRACTICE PATTERNS, PHYSICIANS'; QUALITY IMPROVEMENT; REGISTRIES; STROKE; UNITED STATES; WARFARIN;

EID: 85019205382     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.03.540     Document Type: Article

References (27)

1. January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 64 (2014), e1–e76.
2. Holbrook, A.M., Pereira, J.A., Labiris, R., et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165 (2005), 1095–1106.
3. Hart, R.G., Pearce, L.A., Aguilar, M.I., Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 146 (2007), 857–867.
4. van Walraven, C., Hart, R.G., Singer, D.E., et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 288 (2002), 2441–2448.
5. Go, A.S., Hylek, E.M., Borowsky, L.H., Phillips, K.A., Selby, J.V., Singer, D.E., Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Ann Intern Med 131 (1999), 927–934.
6. Reynolds, M.R., Shah, J., Essebag, V., et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL registry. Am J Cardiol 97 (2006), 538–543.
7. Gallagher, A.M., Rietbrock, S., Plumb, J., van Staa, T.P., Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis?. J Thromb Haemost 6 (2008), 1500–1506.
8. Zimetbaum, P.J., Thosani, A., Yu, H.T., et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?. Am J Med 123 (2010), 446–453.
9. Casciano, J.P., Dotiwala, Z.J., Martin, B.C., Kwong, W.J., The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. J Manag Care Pharm 19 (2013), 302–316.
10. Decker, C., Garavalia, L., Garavalia, B., et al. Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. J Multidiscip Healthc 5 (2012), 129–135.
11. Decker, C., Garavalia, L., Garavalia, B., et al. Exploring barriers to optimal anticoagulation for atrial fibrillation: interviews with clinicians. Am J Med 128 (2015), 1300–1305.
12. Brown, J.D., Shewale, A.R., Dherange, P., Talbert, J.C., A comparison of oral anticoagulant use for atrial fibrillation in the pre- and post-DOAC eras. Drugs Aging 33 (2016), 427–436.
13. Chan, P.S., Oetgen, W.J., Buchanan, D., et al. Cardiac performance measure compliance in outpatients: the American College of Cardiology and National Cardiovascular Data Registry's PINNACLE (Practice Innovation And Clinical Excellence) program. J Am Coll Cardiol 56 (2010), 8–14.
14. Maddox, T.M., Chan, P.S., Spertus, J.A., et al. Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: insights from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 63 (2014), 539–546.
15. Nieuwlaat, R., Olsson, S.B., Lip, G.Y., et al. Guideline-adherent antithrombotic treatment is associated with improved outcomes compared with undertreatment in high-risk patients with atrial fibrillation. The Euro Heart Survey on Atrial Fibrillation. Am Heart J 153 (2007), 1006–1012.
16. Gorin, L., Fauchier, L., Nonin, E., Charbonnier, B., Babuty, D., Lip, G.Y., Prognosis and guideline-adherent antithrombotic treatment in patients with atrial fibrillation and atrial flutter: implications of undertreatment and overtreatment in real-life clinical practice; the Loire Valley Atrial Fibrillation Project. Chest 140 (2011), 911–917.
17. Lauffenburger, J.C., Farley, J.F., Gehi, A.K., Rhoney, D.H., Brookhart, M.A., Fang, G., Factors driving anticoagulant selection in patients with atrial fibrillation in the United States. Am J Cardiol 115 (2015), 1095–1101.
18. Steinberg, B.A., Holmes, D.N., Piccini, J.P., et al. Early adoption of dabigatran and its dosing in US patients with atrial fibrillation: results from the outcomes registry for better informed treatment of atrial fibrillation. J Am Heart Assoc, 2, 2013, e000535.
19. Patel, P.A., Zhao, X., Fonarow, G.C., et al. Novel oral anticoagulant use among patients with atrial fibrillation hospitalized with ischemic stroke or transient ischemic attack. Circ Cardiovasc Qual Outcomes 8 (2015), 383–392.
20. Desai, N.R., Krumme, A.A., Schneeweiss, S., et al. Patterns of initiation of oral anticoagulants in patients with atrial fibrillation- quality and cost implications. Am J Med 127 (2014), 1075–1082.
21. Kirley, K., Qato, D.M., Kornfield, R., Stafford, R.S., Alexander, G.C., National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes 5 (2012), 615–621.
22. Pisters, R., Lane, D.A., Nieuwlaat, R., de Vos, C.B., Crijns, H.J., Lip, G.Y., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138 (2010), 1093–1100.
23. Fosbol, E.L., Holmes, D.N., Piccini, J.P., et al. Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. J Am Heart Assoc, 2, 2013, e000110.
24. Hsu, J.C., Maddox, T.M., Kennedy, K.F., et al. Oral anticoagulant therapy prescription in patients with atrial fibrillation across the spectrum of stroke risk: insights from the NCDR PINNACLE registry. JAMA Cardiol 1 (2016), 55–62.
25. Camm, A.J., Accetta, G., Ambrosio, G., et al. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. Heart 103 (2017), 307–314.
26. Steinberg, B.A., Kim, S., Piccini, J.P., et al. Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. Circulation 128 (2013), 721–728.
27. Hsu, J.C., Akao, M., Abe, M., et al. International Collaborative Partnership for the Study of Atrial Fibrillation (INTERAF): rationale, design, and initial descriptives. J Am Heart Assoc, 5, 2016, e004037.